Stock Research for DXCM


Featured Broker: Ally Invest

Get the due diligence for another stock.


DXCM Stock Chart & Research Data

The DXCM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DXCM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


DXCM Due diligence Resources & Stock Charts

The DXCM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DXCM Detailed Price Forecast - CNN Money CNN View DXCM Detailed Summary - Google Finance
Yahoo View DXCM Detailed Summary - Yahoo! Finance Zacks View DXCM Stock Research & Analysis -

Stock Analysis

TradeIdeas View DXCM Trends & Analysis - Trade-Ideas Barrons View DXCM Major Holders - Barrons
NASDAQ View DXCM Call Transcripts - NASDAQ Seeking View DXCM Breaking News & Analysis - Seeking Alpha
Spotlight View DXCM Annual Report - OTC Report View DXCM OTC Short Report -
TradeKing View DXCM Fundamentals - TradeKing Charts View DXCM SEC Filings - Bar Chart
WSJ View Historical Prices for DXCM - The WSJ Morningstar View Performance/Total Return for DXCM - Morningstar
MarketWatch View the Analyst Estimates for DXCM - MarketWatch CNBC View the Earnings History for DXCM - CNBC
StockMarketWatch View the DXCM Earnings - StockMarketWatch MacroAxis View DXCM Buy or Sell Recommendations - MacroAxis
Bullish View the DXCM Bullish Patterns - American Bulls Short Pains View DXCM Short Pain Metrics -

Social Media Mentions

StockTwits View DXCM Stock Mentions - StockTwits PennyStocks View DXCM Stock Mentions - PennyStockTweets
Twitter View DXCM Stock Mentions - Twitter Invest Hub View DXCM Investment Forum News - Investor Hub
Yahoo View DXCM Stock Mentions - Yahoo! Message Board Seeking Alpha View DXCM Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for DXCM - Insider Cow View Insider Transactions for DXCM - Insider Cow
CNBC View DXCM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DXCM - OTC Markets
Yahoo View Insider Transactions for DXCM - Yahoo! Finance NASDAQ View Institutional Holdings for DXCM - NASDAQ

Stock Charts

FinViz View DXCM Stock Insight & Charts - StockCharts View DXCM Investment Charts -
BarChart View DXCM Stock Overview & Charts - BarChart Trading View View DXCM User Generated Charts - Trading View

Latest Financial News for DXCM

DexCom Inc (NASDAQ:DXCM): Are Analysts Optimistic?
Posted on Tuesday September 18, 2018

DexCom Inc’s (NASDAQ:DXCM): DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The US$12.64bRead More...

10 Boring Stocks Growing Like Weeds
Posted on Friday September 14, 2018

Most investors love a good story — or should I say, a sexy story. In looking for stocks to buy, they like the stories of the companies that are transforming an entire industry or are exploiting a niche that no one even knew existed 20 minutes ago. It’s the rags-to-riches tale, the ground-floor-stock temptation.

See what the IHS Markit Score report has to say about Dexcom Inc.
Posted on Wednesday September 12, 2018

Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 10. Index (PMI) data, output in the Healthcare sector is rising.

DexCom Has Reported 150% Growth in 2018 Year-to-Date
Posted on Monday September 10, 2018

The stock of DexCom (DXCM), the leading pure-play diabetes medtech player, has risen ~150%, from $57.99 on January 2, 2018, to $143.48 on September 7, 2018. In the second quarter, it reported revenues of $242.5 million, a YoY (year-over-year) rise of 42.1%. It reported a 35% YoY rise in revenues for the US market, while sales outside the United States rose 78% YoY in Q2 2018.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.